A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer (original) (raw)

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics 2009. Cancer J Clin 2009; 59: 225–249.
  Article Google Scholar
• Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 2011; 8: 171–176.
  Article PubMed Google Scholar
• Curtin NJ . DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12: 801–817.
  Article CAS PubMed Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139.
  Article CAS PubMed Google Scholar
• Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011–1019.
  Article CAS PubMed PubMed Central Google Scholar
• Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983–991.
  Article CAS PubMed Google Scholar
• Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC . The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012; 9: 144–155.
  Article CAS PubMed Google Scholar
• Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E et al. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer 2012; 118: 2525–2531.
  Article CAS PubMed Google Scholar
• Vilmar AC, Santoni-Rugiu E, Sorensen JB . ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010; 21: 1817–1824.
  Article CAS PubMed Google Scholar
• Fagbemi AF, Orelli B, Scharer OD . Regulation of endonuclease activity in human nucleotide excision repair. DNA Repair 2011; 10: 722–729.
  Article CAS PubMed PubMed Central Google Scholar
• Kirschner K, Melton DW . Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 2010; 30: 3223–3232.
  CAS PubMed Google Scholar
• Tripsianes K, Folkers G, Ab E, Das D, Odijk H, Jaspers NG et al. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 2005; 13: 1849–1858.
  Article CAS PubMed Google Scholar
• Bergstralh DT, Sekelsky J . Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 2008; 24: 70–76.
  Article CAS PubMed Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917–921.
  Article CAS PubMed Google Scholar
• Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao M, Graziano S et al. ERCC1 isoform expression and DNA repair in non-small cell lung cancer. N Engl J Med 2013; 368: 1101–1110.
  Article CAS PubMed PubMed Central Google Scholar
• Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier Y . Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res 2011; 39: 3607–3620.
  Article CAS PubMed PubMed Central Google Scholar
• Wang B, Chu D, Feng Y, Xin Y, Myers P, Post L et al. Novel PARP inhibitors with potent antitumor activity as single-agent and combination therapies. Mol Cancer Ther 2009; 8 (Suppl 12): A121.
  Article Google Scholar
• Patterson M, Murray J, Curtin NJ . Stability of PARP inhibition by BMN 673 in human PBMCs and Leukaemic Cell Cultures. Eur J Cancer 2012; 48 (Suppl 6): 106 (Abstract 348).
  Article Google Scholar
• Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo J 2008; 27: 1368–1377.
  Article CAS PubMed PubMed Central Google Scholar
• Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012; 72: 5588–5599.
  Article CAS PubMed PubMed Central Google Scholar
• Kedar PS, Stefanick DF, Horton JK, Wilson SH . Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res 2012; 10: 360–368.
  Article CAS PubMed PubMed Central Google Scholar
• Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011; 17: 1632–1640.
  Article CAS PubMed PubMed Central Google Scholar
• Langer CJ . Exploring biomarkers in head and neck cancer. Cancer 2012; 118: 3882–3892.
  Article CAS PubMed Google Scholar
• Vilmar AC, Sorensen JB . Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. Eur Respir Rev 2011; 20: 45–52.
  Article CAS PubMed Google Scholar
• Metzger R, Bollschweiler E, Holscher AH, Warnecke-Eberz U . ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol 2010; 6: 1735–1749.
  Article CAS PubMed Google Scholar
• Steffensen KD, Waldstrom M, Jakobsen A . The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19: 820–825.
  Article PubMed Google Scholar
• Chen S, Zhang J, Wang R, Luo X, Chen H . The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung cancer 2010; 70: 63–70.
  Article PubMed Google Scholar
• Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286–2291.
  CAS PubMed Google Scholar
• Rehman FL, Lord CJ, Ashworth A . Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010; 7: 718–724.
  Article CAS PubMed Google Scholar
• Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17: 875–882.
  Article CAS PubMed PubMed Central Google Scholar
• Sijbers AM, van der Spek PJ, Odijk H, van den Berg J, van Duin M, Westerveld A et al. Mutational analysis of the human nucleotide excision repair gene ERCC1. Nucleic Acids Res 1996; 24: 3370–3380.
  Article CAS PubMed PubMed Central Google Scholar
• Dabholkar M, Vionnet J, Parker R, Bostickbruton F, Dobbins A, Reed E . Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes. Oncol Rep 1995; 2: 209–214.
  CAS PubMed Google Scholar
• Sun Y, Li T, Ma K, Tian Z, Zhu Y, Chen F et al. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Cancer Invest 2009; 27: 891–897.
  Article CAS PubMed Google Scholar
• Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013; 34: 739–749.
  Article CAS PubMed Google Scholar
• Niedernhofer LJ, Essers J, Weeda G, Beverloo B, de Wit J, Muijtjens M et al. The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells. Embo J 2001; 20: 6540–6549.
  Article CAS PubMed PubMed Central Google Scholar
• Langelier MF, Planck JL, Roy S, Pascal JM . Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J Biol Chem 2011; 286: 10690–10701.
  Article CAS PubMed PubMed Central Google Scholar
• Langelier MF, Planck JL, Roy S, Pascal JM . Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 2012; 336: 728–732.
  Article CAS PubMed PubMed Central Google Scholar
• Bajrami I, Kigozi A, Van Weverwijk A, Brough R, Frankum J, Lord CJ et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol Med 2012; 4: 1087–1096.
  Article CAS PubMed PubMed Central Google Scholar
• Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010; 16: 6159–6168.
  Article CAS PubMed PubMed Central Google Scholar
• Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111–1115.
  Article CAS PubMed Google Scholar
• Lord CJ, Martin SA, Ashworth A . RNA interference screening demystified. J Clin Pathol 2009; 62: 195–200.
  Article CAS PubMed Google Scholar